The note reveals that Goldman has initiated coverage with a buy rating and $48.90 price target on ResMed's shares. Based on ...

Goldman Sachs initiated coverage on ResMed Inc (NYSE:RMD) with a "Buy" rating and a price target of A$48.9, driven by strong growth prospects in its continuous airway pressure (CPAP) therapy segment.

Goldman Sachs initiated coverage of ResMed (RMD) with a Buy rating and A$48.90 price target The firm says its Buy thesis is based on “robust” ...

The Problem Despite advances in digitizing supply chain management and making data-driven decisions, business planners and executives still expend significant time and effort on understanding ...

Zepbound is a dual-activating medication that combines glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like ...

Adam Maeder, an analyst from Piper Sandler, has initiated a new Hold rating on Resmed (RMD).Stay Ahead of the Market:Discover outperforming ...

The global continuous positive airway pressure (CPAP) market is projected to reach a value of USD 900 million by 2033, ...

KYIV, Ukraine—When the director of Russia’s largest film studio met President Vladimir Putin in the Kremlin last month, he made sure to highlight how he had supported the war effort—by ...

ResMed Inc. (RMD), based in San Diego, California, is a leading provider of cloud-connected devices and digital health solutions, impacting millions of patients worldwide. With a market ...

Keeping CPAP Equipment Clean CPAP manufacturers ... exposure to it may compromise the body's ability to fight respiratory infections. As of February 1, 2020, ResMed has indicated that ozone damage ...

Those deals make January the best time of year to invest in workout equipment and accessories. The Peloton Bike+, for example, has been on semicontinuous sale from November into January.